Systematic review and meta‐analysis of the efficacy and safety of [ 177 Lu ]Lu‐edotreotide ([ 177 Lu ]Lu‐ DOTATOC ) for the treatment of neuroendocrine tumors
Journal of Neuroendocrinology · 2026
DOI: 10.1111/jne.70103 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Neuroendocrinology, 2026. Verfasst von Richard P Baum und 11 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Theranostics Center for Radiomolecular Precision Oncology, Deutsche Klinik für Diagnostik (DKD HELIOS Klinik), Curanosticum Wiesbaden-Frankf…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Somatostatin, Octreotide, Radiopharmaceuticals. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Isotope Technologies Munich (ITM SE).
Abstract (Originalsprache)
[ 177 Lu]Lu‐edotreotide is a radiopharmaceutical therapy (RPT) targeting somatostatin receptors, which are commonly overexpressed on neuroendocrine tumors (NETs). This systematic literature review and meta‐analysis describes the efficacy and safety of [ 177 Lu]Lu‐edotreotide in patients with NETs. To date, there has been no meta‐analysis of data for this specific RPT. PubMed, EMBASE, Cochrane databases, and abstracts from select congresses were searched for eligible studies (February/October 2024). Meta‐analysis was performed using fixed and random‐effects models. The primary objective was to evaluate the efficacy of [ 177 Lu]Lu‐edotreotide in terms of objective response rate (ORR; complete + partial response) in the subgroup of patients with gastro‐enteropancreatic NETs (GEP‐NETs) and those with any NETs, irrespective of origin (All‐NETs). Secondary outcomes included disease control rate (DCR; best overall response of complete response + partial response + stable disease), median progression‐free survival (mPFS), and median overall survival (mOS). Unpublished/updated data were requested from the investigators of the included publications where needed to provide missing information/enable evaluation of additional outcomes. Safety/tolerability data for [ 177 Lu]Lu‐edotreotide were also reviewed. Eight eligible studies were identified for inclusion in the meta‐analysis, all in the advanced disease setting (5/8 included patients with progressive NETs). Most patients had grade 1/2 NETs (grade 1: 11%–63%; 2: 30%–79%; 3: 4%–11%). Updated data were provided for four of these studies. Overall, ORR and DCR were reported in six studies (GEP‐NETs, n = 222; All‐NETs, n = 423), mPFS in five studies (GEP‐NETs, n = 294; All‐NETs, n = 267), and mOS in six studies (GEP‐NETs, n = 256; All‐NETs, n = 408). Meta‐analysis revealed consistently high heterogeneity ( I 2 >70%) across outcomes/patient populations. Patients with GEP‐NETs appeared to have better outcomes than those with All‐NETs in terms of ORR (34% vs. 19%), DCR (78% vs. 57%), mPFS (24.9 vs. 18.6 months), and mOS (44.8 vs. 39.1 months), respectively. Safety/tolerability data were inconsistently reported, but grade 3/4 toxicities were rarely noted during [ 177 Lu]Lu‐edotreotide treatment. These results support the effectiveness and safety of [ 177 Lu]Lu‐edotreotide as a treatment for patients with advanced NETs and suggest a potentially more favorable prognosis for those with GEP‐NETs than for the broader All‐NETs population. However, these results should be interpreted with caution due to the high level of heterogeneity. Encouraging ORRs and high DCRs were noted, indicating that [ 177 Lu]Lu‐edotreotide effectively stabilized disease in most patients. Although safety/tolerability data were inconsistently published across studies, [ 177 Lu]Lu‐edotreotide was generally well tolerated. Overall, these findings suggest that the efficacy and safety of [ 177 Lu]Lu‐edotreotide are in line with those reported for other RPTs in similar clinical settings. Clinical Trial Registration : PROSPERO 2024 CRD42024518028.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Theranostics Center for Radiomolecular Precision Oncology, Deutsche Klinik für Diagnostik (DKD HELIOS Klinik), Curanosticum Wiesbaden-Frankfurt, Wiesbaden, Germany.
- Department of Theragnostics, Division of Nuclear Medicine, ENETS Centre of Excellence (CoE), University Hospital Basel, Basel, Switzerland.
- Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of the Free University of Berlin and of Humboldt University of Berlin, Berlin, Germany.
- Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares (ININ), State of Mexico, Mexico.
- Zentralklinik Bad Berka GmbH, Bad Berka, Germany.
- Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine, University of Messina, Messina, Italy.
ORCID-Profile: Erika Patricia Azorin-Vega, Guillaume P Nicolas
Förderung
- Isotope Technologies Munich (ITM SE)
Zitieren
APA
Baum, R. P., Fricke, J. G., Ruhwedel, T., Amthauer, H., Azorin-Vega, E. P., Hörsch, D., Laudicella, R., Maheshwari, V., Walter, M. A., Polack, B. D., Spiegl, S. F., & Nicolas, G. P. (2026). Systematic review and meta‐analysis of the efficacy and safety of [ 177 Lu ]Lu‐edotreotide ([ 177 Lu ]Lu‐ DOTATOC ) for the treatment of neuroendocrine tumors. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.70103
Vancouver
Baum RP, Fricke JG, Ruhwedel T, Amthauer H, Azorin-Vega EP, Hörsch D, et al. Systematic review and meta‐analysis of the efficacy and safety of [ 177 Lu ]Lu‐edotreotide ([ 177 Lu ]Lu‐ DOTATOC ) for the treatment of neuroendocrine tumors. Journal of Neuroendocrinology. 2026. doi:10.1111/jne.70103
BibTeX
@article{Baum2026,
author = {Baum, Richard P and Fricke, Julia G and Ruhwedel, Tristan and Amthauer, Holger and Azorin-Vega, Erika Patricia and Hörsch, Dieter and Laudicella, Riccardo and Maheshwari, Vikalp and Walter, Martin A and Polack, Berna Degirmenci and Spiegl, Simon F and Nicolas, Guillaume P},
title = {Systematic review and meta‐analysis of the efficacy and safety of [ 177 Lu ]Lu‐edotreotide ([ 177 Lu ]Lu‐ DOTATOC ) for the treatment of neuroendocrine tumors},
journal = {Journal of Neuroendocrinology},
year = {2026},
doi = {10.1111/jne.70103}
}
EUVIMED